广州安必平医药科技股份有限公司 股东减持股份计划时间届满暨减持股份结果公告

Group 1 - The company, Nanjing Qianjing Venture Capital Partnership, held 1,677,265 shares of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd., accounting for 1.79% of the total share capital before the reduction plan [1] - The reduction plan involved Nanjing Qianjing intending to reduce its holdings by up to 1,677,265 shares through centralized bidding and block trading, which represents 1.79% of the company's total share capital [1] - As of December 3, 2025, Nanjing Qianjing had reduced its holdings by 174,922 shares, which is 0.19% of the total share capital, and the reduction plan period has expired [1][3] Group 2 - The reduction subject has no concerted actions with other parties [2] - The actual reduction complied with relevant laws and regulations, and the actual reduction was consistent with the previously disclosed reduction plan [5] - The reduction plan was fully implemented, and there were no violations of the reduction plan or other commitments [5]